Where Is Bal Pharma Share Price Headed Over the Next 3 Years?

The Bal Pharma share price forecast for the next 3 years is a question on many investors’ minds as the stock trades at Rs 91, within a 52 week range of Rs 59.7 to Rs 113. This article lays out a scenario based Bal Pharma share price outlook for 2027, 2028 and 2030, built on the company’s fundamentals, sector trends and the key risks that could change the trajectory. Rather than a single number, the focus here is on the range of outcomes and the assumptions behind each one.

Click Here – Get Free Investment Predictions

Bal Pharma Company Overview

Bal Pharma manufactures active pharmaceutical ingredients and formulations for domestic and export markets, including a Uganda based manufacturing subsidiary. Understanding the business model is the first step in framing any credible Bal Pharma share price forecast, because the durability of earnings ultimately decides where the stock trades.

Company	Bal Pharma
NSE Ticker	BALPHARMA
CMP	Rs 91
52 Week High	Rs 113
52 Week Low	Rs 59.7
Market Cap	Rs 145 Cr
Stock PE	23.1
Book Value	Rs 51.6
ROE	7.87%
ROCE	9.69%
Dividend Yield	1.32%

Where Does Bal Pharma Share Price Stand Today?

The stock currently trades about 19 percent below its 52 week high of Rs 113, which means the market has already tempered some of its optimism. For anyone building a Bal Pharma share price forecast, this correction matters for the Bal Pharma share price forecast starting point, because entry valuations have a large bearing on 3 year returns.

At the current price, Bal Pharma commands a market capitalisation of Rs 145 Cr and trades at a price to earnings multiple of 23.1. The company generates a return on equity of 7.87% and a return on capital employed of 9.69%, which places it in the category of businesses with a recovering profitability profile. These numbers anchor the Bal Pharma share price forecast scenarios that follow. How the broader Nifty 50 index trades over this period will also influence the multiple investors are willing to assign to the stock.

Bal Pharma Share Price Forecast: Key Growth Drivers for the Next 3 Years

Four forces are likely to shape the Bal Pharma share price forecast between now and 2030, and together they explain most of the dispersion in this Bal Pharma share price forecast. Each is discussed below with its likely direction of impact.

Earnings Trajectory and Return Ratios

Stock prices ultimately follow earnings. With a recovering profitability profile at present, the pace at which profits compound over FY27 to FY30 will be the single biggest determinant of the Bal Pharma share price forecast actually playing out. Consistent earnings delivery tends to expand valuation multiples, while misses compress them quickly.

Structural Tailwinds in Indian Pharmaceuticals

The Indian pharmaceutical market continues to grow in high single to low double digits, supported by chronic disease prevalence, better diagnosis rates and premiumisation of therapies. Companies with strong brand equity and field force productivity, like Bal Pharma, are positioned to grow ahead of the market. Sector trends are visible in the Nifty Pharma index, which serves as a useful barometer for the space.

Within the space, investors often benchmark Bal Pharma against peers such as Bafna Pharmaceuticals, Alpa Laboratories and Aarey Drugs & Pharmaceuticals on growth and valuations before forming a view on the Bal Pharma share price forecast.

Company Specific Catalysts

The bull case for Bal Pharma rests on rising API and formulation export demand and expansion of its African manufacturing footprint. If these play out on schedule, the Bal Pharma share price forecast for 2030 could gravitate toward the upper end of the scenario range discussed below.

Macro Environment and Liquidity

The RBI rate cycle, FII flows into Indian equities and overall market valuations will influence the multiple investors are willing to pay. A benign macro backdrop supports the optimistic end of any Bal Pharma share price forecast, while global risk aversion would do the opposite to the Bal Pharma share price outlook.

Bal Pharma Share Price Forecast 2027, 2028 and 2030: Scenario Analysis

The table below presents a scenario based Bal Pharma share price forecast using compounded annual growth assumptions applied to the current market price of Rs 91. These are illustrative ranges, not point predictions, and actual outcomes can fall outside them.

Year	Bear Case	Base Case	Bull Case	Assumption
2027	Rs 94	Rs 100	Rs 110	2% to 14% CAGR on CMP
2028	Rs 96	Rs 110	Rs 125	2% to 14% CAGR on CMP
2030	Rs 100	Rs 130	Rs 165	2% to 14% CAGR on CMP

In the base case scenario of this Bal Pharma share price forecast, the 2030 level works out to roughly Rs 130, implying steady compounding from today’s levels. The bull case of Rs 165 assumes rising API and formulation export demand and expansion of its African manufacturing footprint delivers ahead of expectations, while the bear case of Rs 100 captures a scenario where growth stalls. That is an outcome band of about 10 percent to 81 percent over the period.

Consult a SEBI Registered Investment Advisor Before Acting on Any Forecast

Bull Case vs Bear Case for Bal Pharma Share Price

The Bull Case

The optimistic Bal Pharma share price forecast assumes rising API and formulation export demand and expansion of its African manufacturing footprint. Combined with supportive sector conditions, this could lift both earnings and the valuation multiple, pushing the stock toward Rs 165 by 2030.

The Bear Case

The cautious view centres on the fact that client concentration and pricing pressure in commodity API segments are key risks. If these pressures dominate, the Bal Pharma share price forecast would skew toward the lower band and the stock could stagnate near Rs 100 even by 2030, underperforming broader indices.

Key Risks That Could Change the Bal Pharma Share Price Outlook

• Execution risk: Delays in strategy execution or capacity plans would push the earnings trajectory below the base case assumed in this Bal Pharma share price forecast.
• Valuation risk: At a PE of 23.1, any earnings disappointment can trigger sharp multiple compression before fundamentals stabilise.
• Sector risk: Client concentration and pricing pressure in commodity API segments are key risks.
• Macro risk: A global slowdown, adverse FII flows or unexpected rate moves would compress equity valuations across the market.
• Regulatory risk: Policy, tax or compliance changes affecting the sector can alter the earnings outlook with little warning.

Is Bal Pharma Worth Watching for the Long Term?

For long term investors, the relevant question is not just where the Bal Pharma share price forecast lands in 2030 or what any single Bal Pharma share price forecast says today, but whether the business can compound capital through cycles. The company’s positioning around rising API and formulation export demand and expansion of its African manufacturing footprint gives it a credible growth story, while the risks outlined above define what must be monitored each quarter.

Investors should track quarterly earnings, management commentary and sector data rather than anchoring to any single number from a Bal Pharma share price outlook. Historically, staying focused on business fundamentals has served investors better than chasing price targets, and consulting a SEBI registered advisor before investing remains the prudent approach.

Download the Univest iOS App or Univest Android App to track Bal Pharma share price live.

Conclusion

The Bal Pharma share price forecast for the next 3 years spans Rs 100 to Rs 165 by 2030 under the scenarios discussed, with a base case near Rs 130. Any credible Bal Pharma share price forecast must be updated as facts change, and the path will be decided by earnings delivery, rising API and formulation export demand and expansion of its African manufacturing footprint and the broader market environment. Treat these ranges as a framework for thinking, not a promise of outcomes, and revisit the assumptions as new results come in. Consult a SEBI registered investment advisor before making any investment decision.

What is the Bal Pharma share price forecast for the next 3 years?

Ans. The Bal Pharma share price forecast for the next 3 years is scenario based rather than a single number. By 2030, the illustrative range spans Rs 100 in the bear case to Rs 165 in the bull case, with a base case near Rs 130, depending on earnings delivery and market conditions.

What is the Bal Pharma share price forecast for 2027?

Ans. For 2027, the scenario range works out to Rs 94 to Rs 110, with a base case around Rs 100. This assumes compounding on the current price of Rs 91 and is illustrative, not a guaranteed outcome.

What is the Bal Pharma share price forecast for 2028?

Ans. The 2028 scenario range is Rs 96 to Rs 125, with the base case near Rs 110. Actual levels will depend on earnings growth, sector trends and overall market valuations at the time.

What is the current share price of Bal Pharma?

Ans. Bal Pharma currently trades at around Rs 91 on the NSE, within a 52 week range of Rs 59.7 to Rs 113. Prices change continuously during market hours, so check live quotes before acting.

Is Bal Pharma a good stock for the long term?

Ans. Bal Pharma has a credible long term story built on rising API and formulation export demand and expansion of its African manufacturing footprint, but it also carries risks since client concentration and pricing pressure in commodity API segments are key risks. Long term suitability depends on your risk profile and portfolio, so consult a SEBI registered investment advisor before investing.

What is the Bal Pharma share price outlook for 2030?

Ans. The Bal Pharma share price outlook for 2030 spans Rs 100 to Rs 165 across bear and bull scenarios. Where the stock actually lands will be driven by profit growth, valuation multiples and macro conditions closer to that date.

What are the key risks to the Bal Pharma share price forecast?

Ans. The main risks are execution delays, valuation compression from the current PE of 23.1, sector specific pressures, macro shocks and regulatory changes. Any of these can push the stock below the base case scenario discussed in this article.